Latest research on FTY720

Fingolimod is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis.

Latest findings

Taken together, these findings imply that FTY720 acts indeed by sequestering lymphocytes in secondary lymphoid organs, thereby preventing their migration toward sites of infection and allograft rejection. [source, 2001]
As yet, the molecular target of FTY720 is unknown. [source, 2001]
Homing of CD62L+ (L-selectin) T cells into PPs is increased by FTY720 but expression levels of CD62L, CD49d (VLA4), and CD11a (LFA1) were not altered by FTY720 (9). [source, 2001]
As FTY720 is an amphiphilic molecule, it cannot be excluded that unspecific lipophilic interactions of the hydrocarbon moiety of FTY720 with components of the cell membrane also contribute to the mechanisms of this drug (10). [source, 2001]
This is also underlined by the fact that the effects of FTY720 treatment vary for different cell populations: CD4+ T cells are affected the most, B cells to a lesser degree. [source, 2001]
Perhaps this CCR7-independent mechanism is amplified by FTY720 treatment, which would also explain the observed increase in B cell homing. [source, 2001]
This suggests, that FTY720 might act on the chemokine system as a whole rather than on a specific chemokine receptor. [source, 2001]
This conclusion is also supported by the following observations: (a) while the effect of FTY720 on lymphocyte chemotaxis in vitro is most pronounced toward CCL19 and CCL21, it has also been shown that the chemotaxis to other chemokines is also increased by FTY720 (unpublished data), and (b) although FTY720 treatment augments lymphocyte chemotaxis toward CCL19/CCL21 in vitro (unpublished data), it shows an even more dramatic effect in vivo in mice lacking CCR7 or CCL19 and CCL21. [source, 2001]
It would be of interest to see if FTY720 treatment enables effector T cells to reenter into secondary lymphoid organs and if these cells mount an antiviral immune response at the site of viral replication. [source, 2001]
Further studies are required to find out whether the immunosuppressive effect of FTY720 is solely due to the sequestration of lymphocytes, or whether it interferes with additional lymphocyte activation pathways. [source, 2001]